LabCorp has launched a new test that can be used to assess the capacity of antibodies in patient plasma to inhibit the SARS-CoV-2 virus for the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use. “By leveraging our drug development and diagnostic capabilities, we are working tirelessly to find solutions to prevent and treat COVID-19,” said Paul Kirchgraber, M.D., chief executive officer, LabCorp’s Drug Development business. “The lau...